Price
No data yet.
Social Signal Score
Analyst Ratings
4 analystsRevenue
$458.4KAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Yuichi Iwaki
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 6
- Beta
- 0.63
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 1.07
Financials
Revenue
$458.4K-88.5%Net Income
$-2.31MEBITDA
$-2.54MFree Cash Flow
$-1.92BEPS (diluted)
$-0.05Shares Outstanding (diluted)
49.22M+42.8%Operating Expenses
$2.86MCash & Debt
$25.42MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $409.7K | $-12.00M | $-0.24 |
| 2024 | $0.00 | $-11.05M | $-0.23 |
| 2023 | $1.00M | $-8.57M | $-0.17 |
| 2022 | $0.00 | $-14.07M | $-0.29 |
| 2021 | $4.04M | $-10.13M | $-0.21 |
| 2020 | $0.00 | $-13.85M | $-0.31 |
| 2019 | $0.00 | $-12.94M | $-0.30 |
| 2018 | $0.00 | $-14.68M | $-0.36 |
| 2017 | $0.00 | $-11.16M | $-0.32 |
| 2016 | $0.00 | $-10.87M | $-0.33 |
| 2015 | $0.00 | $-8.85M | $-0.33 |
| 2014 | $0.00 | $-9.20M | $-0.38 |
| 2013 | $6.00M | $-4.03M | $-0.19 |
| 2012 | $802.6K | $-10.96M | $-0.64 |
Valuation
MNOVhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
128+325.00%Social Signal Score
Mentions (5)
- Newsbenzinga.com·7d ago·Negative
MediciNova Drug Falls Short on Liver Fat Parameter, Stock Tumbles MediciNova Inc. (NASDAQ:MNOV) stock is trading lower on Monday after the company reported mixed topline results from its Phase 2 clinical trial evaluating MN-001 (tipelukast) for hypertriglyceridemia and nonalcoholic fatty liver disease (NAFLD) associated with type 2 diabetes mellitus.
View source ↗ - Newsglobenewswire.com·8d ago·Negative
MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast) MN-001 showed statistically significant increases in HDL-C and HDL-P and significant early reduction in triglyceride, a reduction in body weight and a numerical improvement in liver fat MN-001 showed statistically significant increases in HDL-C and HDL-P and significant early reduction in triglyceride, a reduction in body weight and a numerical improvement in liver fat
View source ↗ - Newsglobenewswire.com·12d ago·Neutral
… of MN-166 (Ibudilast) LA JOLLA, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the completion of the last patient, last visit (LPLV) in the double-blind portion of COMBAT-ALS, a Phase 2b/3 clinical trial evaluating MN-166 (ibudilast) for the treatment of Amyotrophic Lateral Sclerosis (ALS). A total of 234 participant…
View source ↗ - Newsglobenewswire.com·28d ago·Neutral
MediciNova to Participate in Two Investor Conferences in September LA JOLLA, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) (the “Company”), announces that Yuichi Iwaki, M.D.
View source ↗ - Newszacks.com·53d ago·Negative
MediciNova (MNOV) Reports Q2 Loss, Tops Revenue Estimates MediciNova (MNOV) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.07 per share a year ago.
View source ↗
Earnings
Thu, Nov 12(in 5 weeks)
Consensus estimate $-0.06 per share
Typical surprise +21.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-0.05 vs $-0.06beat
- Fri, May 15$-0.05 vs $-0.06beat
- Fri, Feb 20$-0.06 vs $-0.10beat
- Thu, Nov 13$-0.06 vs $-0.08beat
- Thu, Aug 14$-0.07 vs $-0.07beat
- Wed, May 14$-0.06 vs $-0.14beat
Estimates and results for MNOV via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by MNOV officers and directors.
- Bought
- $76k
- Sold
- $1.8m
3 trades
7 trades
- 3d Investment Partners Pte. Ltd.sold
- Nagao Hidekisold
- Nagao Hidekisold
- Nagao Hidekisold
- Nagao Hidekisold
- Nagao Hidekisold
- Nagao Hidekisold
- Matsuda Kazukobought
90 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in MNOV.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.